Transformants (e.g., Recombinant Dna Or Vector Or Foreign Or Exogenous Gene Containing, Fused Bacteria, Etc.) Patents (Class 435/252.3)
  • Patent number: 11827904
    Abstract: Stem cells are modified to express an extracellular component including a tag cassette. The tag cassette can be used to detect, enrich, isolate, activate, track, deplete, or eliminate modified cells. The cells can be administered before or following differentiation into a more committed cell type.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 28, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Colleen Delaney, Stanley R. Riddell
  • Patent number: 11697816
    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3?-untranslated region element (3?-UTR element) comprising a nucleic acid sequence which is derived from the 3?-UTR of a FIG4 gene or from a variant of the 3?-UTR of a FIG4 gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3?-UTR element comprising a nucleic acid sequence which is derived from the 3?-UTR of a FIG4 gene or from a variant of the 3?-UTR of a FIG4 gene for the stabilization and/or prolongation of protein expression from a nucleic acid sequence comprising such 3?-UTR element.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: July 11, 2023
    Assignee: CureVac SE
    Inventors: Stefanie Grund, Thomas Schlake
  • Patent number: 11685925
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 27, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Patent number: 11674162
    Abstract: Disclosed are transformed cells and related nucleotide and protein sequences, and fermentation compositions and methods, all of which are related to providing selective advantage in fermentation. For example, a selective advantage results from transformation of a cell with a nucleic acid that allows a transformed cell to metabolize one or more nitrogen-, phosphorous-, and/or sulfur-containing compounds that a native cell of the same species as the transformed cell cannot metabolize, and from fermentation of the transformed cell using one or more feedstocks, such as fractioned grain, which are depleted in or free of conventional nitrogen-, phosphorous-, and/or sulfur-containing compounds that a native cell of the same species as the transformed cell can metabolize. Also disclosed are methods for improved oxygen transfer in an aerobic or microaerobic fermentation.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: June 13, 2023
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Emily H. Greenhagen, Maureen Hamilton, William G. LaTouf, Andrew L. Consiglio, Kyle M. MacEwen, Arthur J. Shaw, IV
  • Patent number: 11649265
    Abstract: The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 16, 2023
    Assignee: AgroSpheres, Inc.
    Inventors: Ameer Hamza Shakeel, Sepehr Zomorodi, Joseph Thomas Frank, Zachery George Davis, Payam Pourtaheri
  • Patent number: 11633456
    Abstract: Compositions and methods for treating hair loss are provided. One embodiment provides a microneedle composition, which when administered to the skin of a subject promotes hair growth. The microneedle compositions include an effective amount of glucocorticoid-induced leucine zipper (GILZ) protein having an amino acid sequence that has 99 or 100% identity to SEQ ID NO: 1, or fragment thereof to promote hair growth when administered to the skin of the subject and a bioerodible, biodegradable, or biosorbable polymer, wherein the composition is formulated as bioerodible, biodegradable, or bioabsorbable microneedles. In one embodiment the GILZ protein or fragment thereof is conjugated to a cell penetrating peptide. The cell penetrating peptide can be TAT GRKKRRQRRRPQ (SEQ ID NO:4) or a variant thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: April 25, 2023
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Mahmood Mozaffari, Babak Baban
  • Patent number: 11628213
    Abstract: Disclosed herein are nucleic acids, vector systems, and vaccines for vaccinating fresh water and marine fish using Ichthyophthirius multifiliis (Ich) i-antigens. In particular, a recombinant attenuated Edwardsiella vaccine (RAEV) vector system is disclosed with regulated delayed attenuation and regulated delayed lysis in vivo attributes that synthesizes Ich protective antigens to enable vaccination of fresh water and marine fish species susceptible to white spot disease. This vaccine construct is designed to exhibit the invasive properties of virulent Edwardsiella at the time of bath immunization and then is programmed to gradually lose virulence attributes and to synthesize protective antigens as a consequence of in vivo cell division as the RAEV colonizes internal effector lymphoid tissues. The ultimate lysis in vivo delivers a bolus of protective antigen along with immunostimulatory molecules to exhibit complete biological containment with no potential for survival in vivo or ex vivo.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: April 18, 2023
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Roy Curtiss, III, Banikalyan Swain
  • Patent number: 11618898
    Abstract: The disclosure provides compositions and methods for producing natural products in microorganisms that are otherwise unexpressed, poorly expressed or poorly transcribed. In particular aspects, the disclosure provides compositions and methods for activating a silent gene or gene cluster with a bacteriophage and/or Streptomyces Antibiotic Regulatory Protein (SARP) transcription factor.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: April 4, 2023
    Assignee: Zymergen Inc.
    Inventors: Oliver Liu, Jeffrey Hoon Kim
  • Patent number: 11555209
    Abstract: The invention provides genetically engineered microorganisms and methods for the biological production of ethylene glycol and precursors of ethylene glycol. In particular, the microorganism of the invention produces ethylene glycol or a precursor of ethylene glycol through one or more of 5,10-methylenetetrahydrofolate, oxaloacetate, citrate, malate, and glycine. The invention further provides compositions comprising ethylene glycol or polymers of ethylene glycol such as polyethylene terephthalate.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 17, 2023
    Assignee: LanzaTech, Inc.
    Inventors: Michael Koepke, Rasmus Jensen
  • Patent number: 11547741
    Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: January 10, 2023
    Assignees: OncoImmune, Inc., Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Mingyue Liu
  • Patent number: 11542494
    Abstract: The present invention pertains to a method for isolating a target nucleic acid including small target nucleic acids from a sample, said method comprising at least the following steps a) binding at least a portion of the target nucleic acid including small target nucleic acids to a nucleic acid binding solid phase comprised in a column by passing the sample through said column, b) performing an enzymatic and/or chemical treatment on the nucleic acid binding solid phase while the target nucleic acid is bound to said solid phase, c) collecting at least a portion of the small target nucleic acids released from the solid phase during said treatment of step b) as flow-through, d) contacting said flow-through which comprises small target nucleic acids mixed with a recovery solution with a nucleic acid binding solid phase for binding the contained small target nucleic acids to said nucleic acid binding solid phase, e) optionally performing an elution.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 3, 2023
    Assignee: QIAGEN GmbH
    Inventors: Vera Holländer, Gabriele Christoffel, Martin Schlumpberger
  • Patent number: 11510974
    Abstract: The present invention relates to a mutated virus. Said virus can be an influenza virus of human or other animal origin. The present invention also relates to a method for preparing the mutated virus, the method comprising introducing UAG codons into positions upstream of the stop codons per se of one or more genes of a viral genome by reverse genetic techniques. The present invention further relates to uses of the mutated virus, for example, as a live attenuated vaccine, or in replication of controllable and safe virus models, and the like.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: November 29, 2022
    Inventors: Demin Zhou, Longlong Si, Xueying Zhou, Ziwei Zhang, Huan Xu, Zhenyu Tian, Chuanling Zhang, Sulong Xiao, Qing Xia, Lihe Zhang
  • Patent number: 11492383
    Abstract: Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active.
    Type: Grant
    Filed: June 24, 2012
    Date of Patent: November 8, 2022
    Inventor: Stephen D. Gillies
  • Patent number: 11479516
    Abstract: The invention relates to methods for promoting fixed nitrogen from atmospheric nitrogen, and related products. Endophytic bacteria having an exogenous nif cluster promote fixed nitrogen for cereal plants.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: October 25, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Christopher A. Voigt, Min-Hyung Ryu, Mi Ryoung Song
  • Patent number: 11426447
    Abstract: The invention relates to a polypeptide, wherein said polypeptide comprises or consists of an EGF-like domain of a neuregulin protein. The invention more over relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. The invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector or said cell for the treatment of tumours of the nervous system, in particular for the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: August 30, 2022
    Inventors: Alexander Schulz, Helen Morrison
  • Patent number: 11396528
    Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 26, 2022
    Assignee: BGI SHENZHEN
    Inventors: Yunxia Tang, Bo Li, Yong Hou, Shuntao Luo, Ying Huang, Geng Liu, Dongli Li, Xiumei Lin
  • Patent number: 11390672
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 19, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Patent number: 11365425
    Abstract: Provided are a resistant protein for use in herbicide dicamba, encoding gene and application thereof, the gene comprising: (a) a nucleotide sequence of an amino acid sequence as shown in SEQ ID NO: 2; or (b) a nucleotide sequence which is complementary to the nucleotide sequence as defined by (a) under stringent conditions; or (c) a nucleotide sequence as shown in SEQ ID NO: 1.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 21, 2022
    Inventors: Jian He, Li Yao, Xingjun Jia, Xiangting Xie, Yechun Wu, Qing Tao, Derong Ding
  • Patent number: 11365401
    Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: June 21, 2022
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Jon Cuccui, Brendan Wren
  • Patent number: 11357842
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 14, 2022
    Assignee: Vaximm AG
    Inventor: Heinz Lubenau
  • Patent number: 11357845
    Abstract: The present invention includes methods for treating and/or immunizing against Haemophilus influenzae, including nontypeable H. influenzae (NTHi). The methods comprise administering a composition comprising H. influenzae proteins OppA and/or LapB.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: June 14, 2022
    Inventors: Hao Shen, Brian Akerley
  • Patent number: 11344604
    Abstract: Disclosed herein is a method of treating or preventing renal disease in a subject suffering from Alport Syndrome, as well a method of treating or preventing chronic kidney disease. The method comprises administering to a subject in need thereof an effective amount of human apolipoprotein M.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: May 31, 2022
    Inventors: Alessia Fornoni, Sandra Merscher
  • Patent number: 11324807
    Abstract: The present invention relates to compositions comprising anakinra, buffer, and optionally at least one osmolyte and optionally further excipients. Further, the present invention relates to use of said compositions for treatment of for example ophthalmic disorders.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 10, 2022
    Assignee: Swedish Orphan Biovitrum AB (publ)
    Inventors: Ebba Florin-Robertsson, Jonas Fransson, Barry D. Moore
  • Patent number: 11319520
    Abstract: Provided herein are filter cake-based systems and methods for cultivating cells and cell biomass therefrom. Provided herein is a system for cultivating cells and cell biomass comprising a filter chamber comprising at least one inlet and at least one outlet, at least one filter support located within the filter chamber, and a filter cake located on the filter support, wherein the filter cake comprises at least one filter aid and a plurality of cells. Provided herein is a method for optimizing the cultivation of cells and cell biomass, comprising providing a filter support, adding at least one filter aid to the filter support, adding a plurality of cells to the filter aid, wherein the cells and the filter aid together comprise a filter cake, growing the cells into a cell biomass in the filter cake, wherein the filter cake is at least partially compressible.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 3, 2022
    Assignee: Upside Foods, Inc.
    Inventor: Konrad Mueller-Auffermann
  • Patent number: 11311027
    Abstract: Nutritive compositions containing an organism having attenuated or no poly(3-hydroxybutyrate) production are provided. These nutritive compositions are useful as feed, such as animal feed and feed additives for ruminants, non-ruminants and aquaculture, etc. Materials and methods for production of these organisms are provided.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 26, 2022
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Paul S. Pearlman, Hugo Federico Cueto Rojas, Gary Smith, Gregory S. Kirby
  • Patent number: 11298420
    Abstract: Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 12, 2022
    Assignee: MEMGEN, LLC
    Inventor: Mark J. Cantwell
  • Patent number: 11261438
    Abstract: Described are mevalonate diphosphate decarboxylase variants having improved activity in converting 3-phosphonoxyisovalerate into isobutene. Such variants can be employed in processes for biologically producing isobutene from 3-hydroxyisovalerate or from 3-hydroxy-3-methylbutyrate into isobutene, for biologically producing isoprenol from mevalonate or from mevalonate-3-phosphate or for biologically producing 1,3-butadiene from 3-hydroxypent-4-enoate or from 3-phosphonoxypent-4-enoate. Also described is an enzyme which is characterized in that it is capable of converting 3-phosphonoxyisovalerate into isobutene with a kcat of more than 0.1 s?1.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: March 1, 2022
    Assignees: Global Bioenergies, Scientist of Fortune, S.A.
    Inventors: Sabine Mazaleyrat, Marc Delcourt, Maria Anissimova, Philippe Marliere
  • Patent number: 11254956
    Abstract: The invention relates to a host cell, preferably a Myceliophthora thermophila cell, which presents a lower expression and/or secretion of non-contributory cellulolytic enzymes, preferably where the non-contributory cellulolytic enzyme is endoglucanase 6 comprising SEQ ID NO: 2, thereby promoting the presence of contributory cellulolytic enzymes in the enzymatic cocktail synthesised by said host cell. The invention also relates to the use of said host cells and the enzymatic cocktails synthesised by said host cells for the production of fermentable sugars of biomass and a method for producing bioproducts, preferably bioethanol, comprising the use of said host cell or the composition according to the invention.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 22, 2022
    Inventors: Bruno Díez García, Noelia Valbuena Crespo, Francisco Reyes Sosa, Antonio Javier Moreno Pérez, Dolores Pérez Gómez, Ana Isabel Platero Gómez, Lucía Martín Pérez, Sandra Gavaldá Martín, Laura Viñas De La Cruz, Laura Sánchez Zamorano, Consolación Álvarez Núñez, María De Los Ángeles Bermúdez Alcántara, Javier Rocha Martín, Laura Ledesma García, Ricardo Arjona Antolín, Juan Luis Ramos Martín
  • Patent number: 11248120
    Abstract: The present invention provides methods for producing a silk protein spinning dope solution suitable for producing high toughness fibres, the thus produced silk protein spinning dope solution, methods for producing fibres using said silk protein spinning dope solution.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: February 15, 2022
    Assignee: Amsilk GmbH
    Inventors: Thomas Scheibel, Axel Leimer, Lin Römer, Lukas Eisoldt, Aniela Heidebrecht, Martha Geffers
  • Patent number: 11213577
    Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: January 4, 2022
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventor: Claudia Gravekamp
  • Patent number: 11207375
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 28, 2021
    Assignees: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley
  • Patent number: 11208447
    Abstract: The present invention relates inter alia to a polynucleotide or viral vector encoding a variant of BPIFB4 (Bactericidal/Permeability Increasing protein family B, member 4) protein and to their use for the treatment of pathologies involving impairment of nitric oxide signalling.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: December 28, 2021
    Assignee: ROXIANT APS
    Inventors: Annibale Alessandro Puca, Carmine Vecchione
  • Patent number: 11198710
    Abstract: The invention is intended to identify glutathione-S-transferase that exhibits the activities to metabolize and detoxify an isoxazoline derivative, such as pyroxasulfone. The invention provides a method for cultivating a transgenic plant into which a nucleic acid encoding a protein (a or b) below has been introduced in the presence of isoxazoline derivatives: (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2; or (b) a protein comprising an amino acid sequence having 80% or higher identity to the amino acid sequence as shown in SEQ ID NO: 2 and having the activity of glutathione-S-transferase.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: December 14, 2021
    Inventors: Yoshitaka Tanetani, Kiyoshi Kawai
  • Patent number: 11186855
    Abstract: The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) an enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5?-phosphate as a coenzyme.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: November 30, 2021
    Inventors: Seiichi Hara, Keiko Kurosawa, Keiichi Ichikawa
  • Patent number: 11179476
    Abstract: The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 23, 2021
    Inventors: Shek Hang Benedict Law, Ching-Hsuan Tung, Vanessa Bellat
  • Patent number: 11174496
    Abstract: There is provided an acetogenic microbial cell which is capable of producing at least one higher alcohol from a carbon source, wherein the acetogenic microbial cell is genetically modified to comprise an increased expression relative to its wild type cell of at least one enzyme, E8, a butyryl-CoA:acetate CoA transferase (cat3). There is also provided a method and use of the cell to produce higher alcohols.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 16, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Thomas Haas, Thomas Bülter, Anja Hecker
  • Patent number: 11168111
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 9, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Patent number: 11141454
    Abstract: Provided is an earthworm protein peptide for preparing a medicine for treating a thrombotic disease. The earthworm protein peptide is any one selected from a group consisting of Leu-Val-Thr-Leu-Gly-Asn-Glu (SEQ ID NO.: 1), Leu-Leu-Ala-Pro-Pro (SEQ ID NO: 2), Leu-Leu-Pro-Ala-Pro (SEQ ID NO: 3) and Thr-Val-Ala-Pro-Phe (SEQ ID NO: 4). The earthworm protein peptide can significantly inhibit the thrombin activity, thus achieving the anticoagulant effect. In vivo, the earthworm protein peptide has a significant inhibitory effect on carrageenan-induced rat tail thrombosis; and in vitro and in vivo studies of rats with thrombus, the earthworm protein peptide provided by the present invention shows good anticoagulant effects. The earthworm protein peptide has effects of thrombosis inhibition, thrombolysis, anticoagulation and fibrinolysis promotion, and can effectively prevent and treat thrombotic disease.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 12, 2021
    Inventors: Jiuxun Zhang, Xuejun Zhang, Mingzhan Tian, Xiping Zhang, Wei Wei
  • Patent number: 11136603
    Abstract: This disclosure relates to genome-scale attenuation or knockout strategies for directing carbon flux to certain carbon based building blocks within the 7-aminoheptanoic acid (7-AHA) and 6-aminohexanoic acid (6-AHA) biosynthesis pathways, for example, to achieve reduced flux to unwanted side products while achieving increased production of desired intermediates and end products. This disclosure also relates to non-naturally occurring mutant bacterial strains comprising one or more gene disruptions in aldehyde reductase and/or aldehyde dehydrogenase genes that are generated to direct carbon flux to certain carbon based building blocks. This disclosure further relates to a method for enhancing production of carbon based building blocks by generating non-naturally occurring mutant bacterial strains, culturing said mutant bacterial strains in the presence of suitable substrates or under desired growth conditions, and substantially purifying the desired end product.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 5, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Stephen Cartman, Jonathan Combe, Alexander B. Foster, Jonathan Kennedy
  • Patent number: 11118171
    Abstract: The invention discloses a recombinant Corynebacterium glutamicum for producing lysine by biofilm continuous fermentation and a construction method thereof, wherein the recombinant Corynebacterium glutamicum is constructed by overexpressing a protease gene FtsH in a Corynebacterium glutamicum; and the construction method comprises the following steps of: (1) performing PCR on a genome of the Corynebacterium glutamicum, and amplifying the FtsH gene to obtain an amplified FtsH gene segment; (2) cloning the FtsH gene segment to an overexpression plasmid to obtain a recombinant plasmid; and (3) introducing the recombinant plasmid into the Corynebacterium glutamicum, and screening to obtain the recombinant Corynebacterium glutamicum.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: September 14, 2021
    Assignee: Nanjing Tech University
    Inventors: Hanjie Ying, Dong Liu, Yong Chen, Qingguo Liu, Pingkai Ouyang, Ming Lei, Huanqing Niu, Bin Yu, Di Zhang, Yuhan Yang, Shishi Wu
  • Patent number: 11103568
    Abstract: Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 31, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Blaine Pfeifer, Charles Jones, Jonathan Lovell
  • Patent number: 11091782
    Abstract: Non-naturally occurring Zymomonas strains useful for the production of 2,3-butanediol are provided.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Min Zhang, Yat-Chen Chou, Mary Ann Franden, Michael E. Himmel
  • Patent number: 11083787
    Abstract: The application describes recombinant BoHV-1 triple mutant viruses that express protective antigens of other bovine respiratory viruses associated with Bovine respiratory disease complex (BRDC).
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 10, 2021
    Assignee: Board of Supervisors of the Louisiana State University and Agricultural and Mechanical College
    Inventor: Shafiqul I. Chowdhury
  • Patent number: 11065296
    Abstract: In various embodiments, a pharmaceutical composition comprising an effective amount of a peptide having the amino acid sequence represented by Formula (I) or an analog thereof, and a pharmaceutically tolerable excipient is described. In some embodiments, the analog of the peptide of Formula (I), comprises the peptide sequence of Formula (I) wherein one or more of the amino acids residues are modified by a) C-terminal modification; b) D-amino acid substitution; and/or c) deletion of one or more amino acid residues. A method of inhibiting the growth of a microorganism comprising contacting the microorganism in a medium with an effective amount of the peptide of Formula (I) or an analog thereof is also described, as are similar methods of treating a disease or disorder associated with microbial activity in a subject by administering an effective amount of a peptide of Formula (I) or an analog thereof and a pharmaceutically tolerable excipient to the subject.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: July 20, 2021
    Assignee: City University of Hong Kong
    Inventors: Yun Wah Lam, Doris Wai Ting Au, Hongyan Sun
  • Patent number: 11066465
    Abstract: Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 20, 2021
    Inventors: Daniel Victor Perlroth, Wah Yuen To, Hong Liang
  • Patent number: 11066456
    Abstract: The present invention provides TREM2 constructs. TREM2 constructs of the invention are polynucleotide sequences encoding a polypeptide, wherein the polypeptide comprises at least one TREM2 or fragment thereof and a targeting moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by TREM2 constructs, vectors comprising TREM2 constructs, isolated cells comprising said vectors, and methods of use thereof.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 20, 2021
    Assignee: Washington University
    Inventors: Marco Colonna, Yarning Wang, Marina Celia
  • Patent number: 11046735
    Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: June 29, 2021
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Michelle Leslie
  • Patent number: 11046936
    Abstract: The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: June 29, 2021
    Assignee: Codexis, Inc.
    Inventors: Margie Tabuga Borra-Garske, Oscar Alvizo, Melissa Ann Mayo, Stephan Jenne, Auric Anthony Sowell-Kantz, Carmela Molinaro
  • Patent number: 11040086
    Abstract: An active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof, which belongs to the technical field of preparing drugs for treating retinal neurodegenerative diseases, are described. The amino acid sequence of the active peptide for enhancing the phagocytic functions of retinal pigment epithelium described in the disclosure was as shown in SEQ ID NO.1. The active peptide of the present invention has biological characteristics similar to those of Gas6 full-length proteins, with an effect of enhancing the phagocytic functions of retinal pigment epithelium.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 22, 2021
    Assignee: Beijing Tongren Hospital, Capital Medical University
    Inventors: Jingxue Zhang, Shen Wu, Ningli Wang
  • Patent number: RE48805
    Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (AAD) fusion protein for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, binds to human serum albumin (HSA) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. The AAD fusion protein can also be used as a component for detection and quantitative analysis of arginine in a testing kit for various samples including blood, food and analytical samples.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: November 2, 2021
    Assignee: Vision Global Holdings Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung